C-type lectin receptor-associated innate immune signaling pathways (CLR-TBK1-NFkB-p38)

The C-type lectin receptor (CLR)-associated innate immune signaling pathways, involving TANK-binding kinase 1 (TBK1), NF-κB, and p38 MAPK, constitute a critical network for pathogen recognition and inflammatory response (PMID: 25712213). CLRs like Dectin-1 and Mincle detect fungal and bacterial ligands, initiating cascades that activate the transcription factor NF-κB and the kinase p38 to produce pro-inflammatory cytokines such as TNF-α and IL-6 (UniProt P19838, Q16539). Simultaneously, TBK1 is recruited to mediate the production of Type I interferons, which are vital for antiviral and antibacterial defense (UniProt Q9UHD2). Dysregulation of this integrated network is implicated in chronic inflammatory diseases, autoimmune disorders, and the promotion of a pro-tumorigenic microenvironment in various cancers (PMID: 30108457). Pharmacological intervention typically targets individual nodes, such as TBK1 with inhibitors like Amlexanox or p38 MAPK with agents like Losmapimod, to treat inflammatory conditions (PubChem). However, the broad physiological impact of these pathways necessitates careful patient selection and monitoring for safety concerns like systemic immunosuppression.

Other names

TBK1/NF-κB/p38/CLR-associated innate immune pathwaysCLR signaling networkC-type lectin receptor signaling cascadeDectin-1/Mincle-mediated immune response

Inhibition of TBK1 or p38 MAPK kinase activity or modulation of NF-κB transcriptional activation through proteasome inhibition or upstream receptor blockade.